GB1200902A — Iron-dextran complexes
Assigned to Fisons Pharmaceuticals Ltd · Expires 1970-08-05 · 56y expired
What this patent protects
1,200,902. Iron-dextran complex. FISONS PHARMACEUTICALS Ltd. 29 April, 1968 [13 May, 1967], No. 22280/67. Heading C3U. [Also in Division A5] A complex of Fe(OH) 3 and dextran is made by slowly adding alkali to an aqueous solution of at least one water-soluble ferric salt at 20-4…
USPTO Abstract
1,200,902. Iron-dextran complex. FISONS PHARMACEUTICALS Ltd. 29 April, 1968 [13 May, 1967], No. 22280/67. Heading C3U. [Also in Division A5] A complex of Fe(OH) 3 and dextran is made by slowly adding alkali to an aqueous solution of at least one water-soluble ferric salt at 20-40‹ C. at a rate such as to convert 10-90% of the salt to colloidal Fe(OH) 3 in not less than 30 minutes, subsequently adding an aqueous solution of dextran (as defined) and adjusting the pH to 4-7 followed by heating at 50‹ C. or above for a period sufficient to form a stable complex. The dextran is defined as being hydrogenated, oxidized, alkali treated according to Specification 1,199,951, or partially depolymerized. Examples describe the treatment of FeCl 3 solution with Na 2 CO 3 , followed by addition of a solution of partially-depolymerized, bromine-oxidized dextran and heating at 80‹ C. or autoclaving. The product is useful therapeutically.
Drugs covered by this patent
- Injectafer (FERRIC CARBOXYMALTOSE) · Am Regent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.